Nicolet Bankshares Inc. grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 1.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,785 shares of the company’s stock after purchasing an additional 159 shares during the quarter. Nicolet Bankshares Inc.’s holdings in Merck & Co., Inc. were worth $671,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. boosted its stake in shares of Merck & Co., Inc. by 186.4% during the fourth quarter. Contravisory Investment Management Inc. now owns 653 shares of the company’s stock valued at $50,000 after purchasing an additional 425 shares during the period. Arlington Partners LLC lifted its stake in Merck & Co., Inc. by 93.5% in the fourth quarter. Arlington Partners LLC now owns 828 shares of the company’s stock worth $63,000 after acquiring an additional 400 shares during the period. Advisors Preferred LLC purchased a new stake in Merck & Co., Inc. in the fourth quarter worth $66,000. Financial Gravity Companies Inc. purchased a new stake in Merck & Co., Inc. in the fourth quarter worth $66,000. Finally, Transamerica Financial Advisors Inc. lifted its stake in Merck & Co., Inc. by 61.4% in the fourth quarter. Transamerica Financial Advisors Inc. now owns 1,293 shares of the company’s stock worth $99,000 after acquiring an additional 492 shares during the period. 73.39% of the stock is owned by hedge funds and other institutional investors.
In other news, CEO Kenneth C. Frazier sold 92,913 shares of the firm’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $80.03, for a total transaction of $7,435,827.39. Following the completion of the transaction, the chief executive officer now directly owns 784,863 shares in the company, valued at $62,812,585.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Merck & Co., Inc. purchased 4,121,683 shares of Merck & Co., Inc. stock in a transaction dated Monday, April 8th. The shares were bought at an average price of $16.00 per share, with a total value of $65,946,928.00. The disclosure for this purchase can be found here. Insiders have sold 1,094,632 shares of company stock valued at $87,840,652 in the last three months. Insiders own 0.32% of the company’s stock.
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Friday, February 1st. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.03 by $0.01. The business had revenue of $11 billion during the quarter, compared to analyst estimates of $10.93 billion. Merck & Co., Inc. had a return on equity of 36.83% and a net margin of 14.71%. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.98 earnings per share. Sell-side analysts anticipate that Merck & Co., Inc. will post 4.65 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, April 5th. Shareholders of record on Friday, March 15th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.72%. The ex-dividend date was Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio is currently 50.69%.
A number of analysts recently commented on MRK shares. Credit Suisse Group set a $86.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Thursday, December 13th. Morgan Stanley set a $81.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Thursday, December 20th. Citigroup set a $65.00 price target on Merck & Co., Inc. and gave the stock a “hold” rating in a research note on Thursday, December 20th. Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $83.00 price target for the company in a research note on Friday, January 4th. Finally, BMO Capital Markets lowered Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price target for the company. in a research note on Wednesday, January 23rd. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $77.83.
WARNING: “Nicolet Bankshares Inc. Has $671,000 Stake in Merck & Co., Inc. (MRK)” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.com-unik.info/2019/04/11/nicolet-bankshares-inc-has-671000-stake-in-merck-co-inc-mrk.html.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Featured Story: How to read a candlestick chart
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.